Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto.

Alzheimer’s disease Cognitive impairment Dementia Neurovascular unit Policy Prevention Resilience Risk factor reduction Stroke Treatment

Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
22 Sep 2019
Historique:
entrez: 24 9 2019
pubmed: 24 9 2019
medline: 24 9 2019
Statut: aheadofprint

Résumé

The incidence of stroke and dementia are diverging across the world, rising for those in low-and middle-income countries and falling in those in high-income countries. This suggests that whatever factors cause these trends are potentially modifiable. At the population level, neurological disorders as a group account for the largest proportion of disability-adjusted life years globally (10%). Among neurological disorders, stroke (42%) and dementia (10%) dominate. Stroke and dementia confer risks for each other and share some of the same, largely modifiable, risk and protective factors. In principle, 90% of strokes and 35% of dementias have been estimated to be preventable. Because a stroke doubles the chance of developing dementia and stroke is more common than dementia, more than a third of dementias could be prevented by preventing stroke. Developments at the pathological, pathophysiological, and clinical level also point to new directions. Growing understanding of brain pathophysiology has unveiled the reciprocal interaction of cerebrovascular disease and neurodegeneration identifying new therapeutic targets to include protection of the endothelium, the blood-brain barrier, and other components of the neurovascular unit. In addition, targeting amyloid angiopathy aspects of inflammation and genetic manipulation hold new testable promise. In the meantime, accumulating evidence suggests that whole populations experiencing improved education, and lower vascular risk factor profiles (e.g., reduced prevalence of smoking) and vascular disease, including stroke, have better cognitive function and lower dementia rates. At the individual levels, trials have demonstrated that anticoagulation of atrial fibrillation can reduce the risk of dementia by 48% and that systolic blood pressure lower than 140 mmHg may be better for the brain. Based on these considerations, the World Stroke Organization has issued a proclamation, endorsed by all the major international organizations focused on global brain and cardiovascular health, calling for the joint prevention of stroke and dementia. This article summarizes the evidence for translation into action. © 2019 the Alzheimer's Association and the World Stroke Organisation. Published by Elsevier Inc. All rights reserved.

Identifiants

pubmed: 31543058
doi: 10.1177/1747493019871915
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1747493019871915

Subventions

Organisme : Medical Research Council
ID : MR/J006971/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1001245
Pays : United Kingdom
Organisme : The Dunhill Medical Trust
ID : R380R/1114
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CS/15/5/31475
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701120
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom

Auteurs

Vladimir Hachinski (V)

Department of Clinical Neurological Sciences, Western University, Ontario, Canada.

Karl Einhäupl (K)

Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Detlev Ganten (D)

Charité - Universitätsmedizin Berlin, Berlin, Germany.

Suvarna Alladi (S)

Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.

Carol Brayne (C)

Department of Public Health and Primary Care in the University of Cambridge, Cambridge, UK.

Blossom C M Stephan (BCM)

Institute of Mental Health, Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.

Melanie D Sweeney (MD)

Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Berislav Zlokovic (B)

Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Yasser Iturria-Medina (Y)

Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Costantino Iadecola (C)

Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.

Nozomi Nishimura (N)

Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.

Chris B Schaffer (CB)

Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.

Shawn N Whitehead (SN)

Department of Anatomy and Cell Biology, Western University, Ontario, Canada.

Sandra E Black (SE)

Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Leif Østergaard (L)

Department of Clinical Medicine, Center of Functionally Integrative Neuroscience, Aarhus University, Aarhus, Denmark.
Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark.

Joanna Wardlaw (J)

Centre for Clinical Brain Sciences, Edinburgh Imaging, UK Dementia Research Institute, University of Edinburgh, Scotland, UK.

Steven Greenberg (S)

Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

Leif Friberg (L)

Department of Clinical Sciences, Karolinska Institute, Stockholm, Sweden.

Bo Norrving (B)

Department of Clinical Sciences, Neurology, Lund University, Lund, Sweden.

Brian Rowe (B)

Department of Emergency Medicine and School of Public Health, University of Alberta, Edmonton, Alberta, Canada.

Yves Joanette (Y)

Canadian Institute of Health and Research, Ottawa, Canada.

Werner Hacke (W)

Department of Neurology, Heidelberg University, Heidelberg, Germany.

Lewis Kuller (L)

Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.

Martin Dichgans (M)

Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-Universität LMU, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.

Matthias Endres (M)

Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
ExcellenceCluster NeuroCure, Charité-Universitätsmedizin Berlin, Berlin, Germany.
German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Berlin, Germany.
German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
Berlin Institute of Health (BIH), Berlin, Germany.

Zaven S Khachaturian (ZS)

Prevent Alzheimer Disease (PAD2020), Potamac, MD, USA.

Classifications MeSH